Granted Patent
B2
US 12,233,042 · App. 17/471,853 · Granted Feb 25, 2025
Treatment of cutaneous disorders
Inventors:
Howard Welgus (West Chester, PA); Matthew Gene Davidson (Venice, CA); Jayson Michael Rieger (Charlottesville, VA)
Assignee:
Verrica Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
Claims (29)
1. A composition comprising:
cantharidin, wherein the composition comprises greater than or equal to 0.7 and less than or equal to 0.9 weight per weight percent of cantharidin;
acetone, wherein the composition comprises greater than or equal to 55 and less than or equal to 65 weight per weight percent of acetone;
ethanol, wherein the composition comprises greater than or equal to 25 and less than or equal to 35 weight per weight percent of ethanol;
castor oil, wherein the composition comprises greater than or equal to 1.2 and less than or equal to 1.6 weight per weight percent of castor oil;
nitrocellulose, wherein the composition comprises greater than or equal to 3 and less than or equal to 6 weight per weight percent of nitrocellulose;
hydroxypropyl cellulose, wherein the composition comprises greater than or equal to 0.5 and less than or equal to 1 weight per weight percent of hydroxypropyl cellulose; and
camphor, wherein the composition comprises greater than or equal to 0.5 and less than or equal to 1.5 weight per weight percent of camphor.
2. The composition of claim 1 further comprising denatonium benzoate, wherein the composition comprises greater than or equal to 0.001 and less than or equal to 0.01 weight per weight percent of denatonium benzoate.
3. The composition of claim 1 further comprising gentian violet, wherein the composition comprises greater than or equal to 0.0001 and less than or equal to 0.001 weight per weight percent of gentian violet.
4. The composition of claim 1 , wherein the composition comprises greater than or equal to 58 and less than or equal to 62 weight per weight percent of acetone.
5. The composition of claim 1 , wherein the composition comprises greater than or equal to 28 and less than or equal to 32 weight per weight percent of ethanol.
6. The composition of claim 2 , wherein the composition comprises greater than or equal to 0.004 and less than or equal to 0.008 weight per weight percent of denatonium benzoate.
7. The composition of claim 3 , wherein the composition comprises greater than or equal to 0.0002 and less than or equal to 0.0008 weight per weight percent of gentian violet.
8. A single use applicator device comprising the composition of claim 1 .
9. A method of treating a subject having a skin lesion comprising administering the composition of claim 1 to at least a portion of the skin lesion.
10. The method of claim 9 , wherein the skin lesion is molluscum contagiosum.
11. The method of claim 9 , wherein the skin lesion is seborrheic keratosis, actinic keratosis, milia, age spots, porokeratosis, or skin cancer.
12. The method of claim 9 , wherein the skin lesion is a wart.
13. The method of claim 12 , wherein the wart is a common wart, plantar wart, or genital wart.
14. The method of claim 9 , wherein at least a portion of the composition remains on the skin lesion for greater than or equal to 12 hours and less than or equal to 48 hours.
15. The method of claim 9 , wherein the plasma concentration of cantharidin in the subject is less than or equal to 3.3 ng/ml after at least 12 hours after the administration step.
16. The method of claim 9 , wherein at least a portion of the composition remains on the skin lesion for up to 24 hours.
17. The composition of claim 1 further comprising:
denatonium benzoate, wherein the composition comprises greater than or equal to 0.001 and less than or equal to 0.01 weight per weight percent of denatonium benzoate; and
gentian violet, wherein the composition comprises greater than or equal to 0.0001 and less than or equal to 0.001 weight per weight percent of gentian violet.
18. The method of claim 12 , wherein the wart is a common wart.
19. The method of claim 12 , wherein the wart is a plantar wart.
20. The method of claim 12 , wherein the wart is a genital wart.
Assignments (5)
SECURITY INTEREST
Recorded Aug 7, 2026
From: VERRICA PHARMACEUTICALS INC.
To: PD JOINT HOLDINGS, LLC SERIES 2016-B
Reel/Frame 075569/0744 →
RELEASE OF SECURITY INTEREST
Recorded Nov 25, 2025
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
To: VERRICA PHARMACEUTICALS INC.
Reel/Frame 073715/0332 →
SECURITY INTEREST
Recorded Jul 11, 2025
From: VERRICA PHARMACEUTICALS INC.
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 071893/0078 →
SECURITY INTEREST
Recorded Jul 27, 2023
From: VERRICA PHARMACEUTICALS INC.
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 064415/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 10, 2022
From: WELGUS, HOWARD; DAVIDSON, MATTHEW GENE; RIEGER, JAYSON MICHAEL
To: VERRICA PHARACEUTICALS, INC.
Reel/Frame 059218/0015 →
Continuity (3)
Continuation
16619675
Provisional Application
62516061
· Jun 6, 2017
References Cited (230)
US 600556A
· Schupphaus
· 1898
[cited by applicant]
US 1744893A
· Hein
· 1930
[cited by applicant]
US 3393962A
· Maurice
· 1968
[cited by applicant]
US 3981924A
· Hall
· 1976
[cited by applicant]
US 4143050A
· Rossy et al.
· 1979
[cited by applicant]
US 4148874A
· Smith
· 1979
[cited by applicant]
US 4157967A
· Meyst et al.
· 1979
[cited by applicant]
US 4298752A
· Dauben et al.
· 1981
[cited by applicant]
US 4299006A
· Cruz
· 1981
[cited by applicant]
US 4413154A
· Dessau
· 1983
[cited by applicant]
US 4895727A
· Allen
· 1990
[cited by applicant]
US 5445462A
· Johnson et al.
· 1995
[cited by applicant]
US 5464855A
· Capiris et al.
· 1995
[cited by applicant]
US 5590780A
· O'Meara
· 1997
[cited by applicant]
US 5702694A
· Chamness
· 1997
[cited by applicant]
US 5727892A
· Baudin
· 1998
[cited by applicant]
US 6066124A
· Caillouette
· 2000
[cited by applicant]
US D436661S
· Berry
· 2001
[cited by applicant]
US 6379342B1
· Levinson
· 2002
[cited by applicant]
US 6547467B2
· Quintero
· 2003
[cited by applicant]
US 6673031B2
· Mark
· 2004
[cited by applicant]
US 6811342B2
· Pauchet
· 2004
[cited by applicant]
US 8518076B2
· Stenton
· 2013
[cited by applicant]
US 8871801B2
· Levitt
· 2014
[cited by applicant]
US D771250S
· Zhang et al.
· 2016
[cited by applicant]
US D772407S
· Zhang et al.
· 2016
[cited by applicant]
US 9480691B1
· Roth
· 2016
[cited by applicant]
US D801830S
· Zhang et al.
· 2017
[cited by applicant]
US D868160S
· Lam
· 2019
[cited by applicant]
US D900312S
· Davidson et al.
· 2020
[cited by applicant]
US D933494S
· Tempfli et al.
· 2021
[cited by applicant]
US D938587S
· Fujii et al.
· 2021
[cited by applicant]
US D947027S
· Marik
· 2022
[cited by applicant]
US D957625S
· Reynolds
· 2022
[cited by applicant]
US 20030072814A1
· Maibach et al.
· 2003
[cited by applicant]
US 20040011830A1
· Kim
· 2004
[cited by applicant]
US 20040152766A1
· Au-Yeung et al.
· 2004
[cited by applicant]
US 20040162533A1
· Alley
· 2004
[cited by applicant]
US 20050019418A1
· Crutchfield
· 2005
[cited by examiner]
US 20050111900A1
· Fazzolari et al.
· 2005
[cited by applicant]
US 20060110415A1
· Gupta
· 2006
[cited by applicant]
US 20060180613A1
· Manesis
· 2006
[cited by applicant]
US 20070000566A1
· Gueret
· 2007
[cited by applicant]
US 20070111954A1
· Crutchfield et al.
· 2007
[cited by applicant]
US 20070187437A1
· Lord
· 2007
[cited by applicant]
US 20070275045A1
· Evans et al.
· 2007
[cited by applicant]
US 20080146674A1
· Rosenberg et al.
· 2008
[cited by applicant]
US 20090311028A1
· Odermatt et al.
· 2009
[cited by applicant]
US 20110208136A1
· Sollingen et al.
· 2011
[cited by applicant]
US 20120016320A1
· Lin
· 2012
[cited by applicant]
US 20120148520A1
· Strobel et al.
· 2012
[cited by applicant]
US 20120190658A1
· Studin
· 2012
[cited by applicant]
US 20120312709A1
· Kaufman
· 2012
[cited by applicant]
US 20200270269A1
· Davidson et al.
· 2020
[cited by applicant]
US 20210070771A1
· Davidson et al.
· 2021
[cited by applicant]
US 20210386703A1
· Davidson
· 2021
[cited by applicant]
CH 204207A
· 1939
[cited by applicant]
CN 1571795A
· 2005
[cited by applicant]
CN 1966508A
· 2007
[cited by applicant]
CN 101012230A
· 2007
[cited by applicant]
CN 101108853A
· 2008
[cited by applicant]
CN 101108854A
· 2008
[cited by applicant]
CN 101161654A
· 2008
[cited by applicant]
CN 101453923A
· 2009
[cited by applicant]
CN 101108853B
· 2010
[cited by applicant]
CN 101798309A
· 2010
[cited by applicant]
CN 101036774B
· 2010
[cited by applicant]
CN 102146086A
· 2011
[cited by applicant]
CN 102268006A
· 2011
[cited by applicant]
CN 102336765A
· 2012
[cited by applicant]
CN 102526146A
· 2012
[cited by applicant]
CN 202730045A
· 2013
[cited by applicant]
CN 202920809U
· 2013
[cited by applicant]
CN 102268006B
· 2013
[cited by applicant]
CN 103923095A
· 2014
[cited by applicant]
CN 204817029U
· 2015
[cited by applicant]
CN 105636637A
· 2016
[cited by applicant]
CN 106674248A
· 2017
[cited by applicant]
DE 20016131U1
· 2000
[cited by applicant]
EP 0841059A1
· 1998
[cited by applicant]
GB 587994A
· 1947
[cited by applicant]
JP S51141863A
· 1976
[cited by applicant]
JP H3202002A
· 1991
[cited by applicant]
JP 05058914
· 1993
[cited by applicant]
JP H05255367A
· 1993
[cited by applicant]
JP H07500980A
· 1995
[cited by applicant]
JP 10114626A
· 1998
[cited by applicant]
JP 11319064
· 1999
[cited by applicant]
JP 11335303
· 1999
[cited by applicant]
JP 2004059446A
· 2004
[cited by applicant]
JP 2005187330A
· 2005
[cited by applicant]
JP 2007269693A
· 2007
[cited by applicant]
JP 2008505960A
· 2008
[cited by applicant]
JP 2010516410A
· 2010
[cited by applicant]
JP 2010235471A
· 2010
[cited by applicant]
JP 4739621B2
· 2011
[cited by applicant]
JP 2001245964A
· 2011
[cited by applicant]
JP 201297152A
· 2012
[cited by applicant]
JP 2013507367A
· 2013
[cited by applicant]
JP 2016528015A
· 2016
[cited by applicant]
JP 2017513907A
· 2017
[cited by applicant]
KR 1020050032154A
· 2005
[cited by applicant]
KR 100786203B1
· 2007
[cited by applicant]
KR 1020160045086A
· 2016
[cited by applicant]
KR 1020170029413A
· 2017
[cited by applicant]
WO WO2008092068A2
· 2008
[cited by applicant]
WO WO2010002476A1
· 2010
[cited by applicant]
WO WO2010079513A2
· 2010
[cited by applicant]
WO WO2011035019A1
· 2011
[cited by applicant]
WO WO2012131238A1
· 2012
[cited by applicant]
WO WO2013189841A1
· 2013
[cited by applicant]
WO WO2015027111A1
· 2015
[cited by applicant]
WO WO2016006693A1
· 2016
[cited by applicant]
WO WO2016100732A2
· 2016
[cited by applicant]
WO WO2016118633A1
· 2016
[cited by applicant]
WO WO2016134130A1
· 2016
[cited by applicant]
WO WO2018226894A1
· 2018
[cited by applicant]
Extended European Search Report, mailed Mar. 10, 2017, in connection with EP 14837297.2.
[cited by applicant]
International Search Report and Written Opinion, mailed Nov. 20, 2014, in connection with PCT/US2014/052184.
[cited by applicant]
International Preliminary Report on Patentability, mailed Mar. 3, 2016, in connection with PCT/US2014/052184.
[cited by applicant]
Extended European Search Report, mailed Oct. 26, 2018, in connection with EP 15871116.8.
[cited by applicant]
International Search Report and Written Opinion, mailed Jul. 14, 2016, in connection with PCT/US2015/066487.
[cited by applicant]
International Preliminary Report on Patentability, mailed Jun. 29, 2017, in connection with PCT/US2015/066487.
[cited by applicant]
Supplementary European Search Report, mailed Aug. 8, 2018, in connection with EP 16740681.8.
[cited by applicant]
Extended European Search Report, mailed Dec. 4, 2018, in connection with EP 16740681.8.
[cited by applicant]
International Search Report and Written Opinion, mailed Jul. 1, 2016, in connection with PCT/US2016/014139.
[cited by applicant]
International Preliminary Report on Patentability, mailed Aug. 3, 2017, in connection with PCT/US2016/014139.
[cited by applicant]
Extended European Search Report, mailed Feb. 2, 2021, in connection with EP 18813599.0.
[cited by applicant]
Invitation to Pay Additional Fees, mailed Aug. 27, 2018, in connection with PCT/US2018/O3653.
[cited by applicant]
International Search Report and Written Opinion, mailed Oct. 22, 2018, in connection with PCT/US2018/036353.
[cited by applicant]
International Preliminary Report on Patentability, mailed Dec. 19, 2019, in connection with PCT/US2018/036353.
[cited by applicant]
Invitation to Pay Additional Fees, mailed Sep. 20, 2018, in connection with PCT/US2018/037808.
[cited by applicant]
International Search Report and Written Opinion, mailed Nov. 13, 2018, in connection with PCT/US2018/037808.
[cited by applicant]
International Preliminary Report on Patentability mailed Dec. 26, 2019 in connection with International Application No. PCT/US2018/037808.
[cited by applicant]
Partial Supplementary European Search Report for Application No. EP 18864069.2, mailed Apr. 12, 2021.
[cited by applicant]
Extended European Search Report for Application No. EP 18864069.2, mailed Jul. 7, 2021.
[cited by applicant]
Invitation to Pay Additional Fees, mailed Dec. 10, 2018, in connection with PCT/US2018/054373.
[cited by applicant]
International Search Report and Written Opinion, mailed Apr. 3, 2019 in connection with PCT/US2018/054373.
[cited by applicant]
International Preliminary Report on Patentability mailed Apr. 16, 2020, in connection with International Application No. PCT/US2018/054373.
[cited by applicant]
[No Author Listed] CAS RN 27607-77-8. Entered STN: Nov. 1, 19846. 28 pages.
[cited by applicant]
[No Author Listed] CAS RN 76262-87-8. Entered STN: Nov. 1, 19846. 19 pages.
[cited by applicant]
[No Author Listed] CAS RN 89672-77-5. Entered STN: Nov. 1, 19846. 29 pages.
[cited by applicant]
[No Author Listed] Dormer Laboratories, “Cantharone and Cantharone Plus” sales brochure. Publication date unknown.
[cited by applicant]
Aitken et al., Fragmentation patterns in the gas-phase pyrolysis of some bi- and tri-cyclic sulfolanes related to the 8-thiabicyclo[4.3.0]non-3-ene 8,8-dioxide ring system . J Chem Soc. Perkin Transactions 1. 1994;16:23…
[cited by applicant]
Anderson et al., Practical Process Research and Development. 1st Edition. Academic Press. Mar. 20, 2000. 81-111.
[cited by applicant]
Aono et al., New method for generation of thiocarbonyl ylides from bis(trimethylsilylmethyl) sulfoxides and their application to cycloadditions. Heterocycles. 1995;40(1):249-60.
[cited by applicant]
Augé et al., Catalysis by Lithium Cation: Lithium Trifluoromethanesulfonate as a Substitute for Lithium Perchlorate in Cycloadditions. Synlett 2000;6:877-9.
[cited by applicant]
Bagatell, Studies On Biological Factors In Acantholysis. J Invest Dermatol. Nov. 1964;43:357-61.
[cited by applicant]
Baker et al., Biotin; the structure of 2-alkyldihydrothiophene-3,4-dicarboxylic acids. J Org Chem. Jan. 1948;13(1):123-33. doi: 10.1021/jo01159a017.
[cited by applicant]
Bouacha et al., A theoretical study of the mechanism, stereoselectivity and Lewis acid catalyst on the Diels-Alder cycloaddition between furan and activated alkenes. Tetrahedron Letters. 2013;54:4030-4033.
[cited by applicant]
Braddock et al., Stereochemistry of the Catalysed Diels-Alder Reaction between Cyclopentadiene and Dimethyl Monothionofumarate; Soft versus Hard Lewis Acids. J. Chem. Soc. Chem. Commun. Jan. 1, 1993;16:1244-6. doi: http…
[cited by applicant]
Brion et al., On the lewis acid catalyzed diels-alder reaction of furan. regio- and stereospecific synthesis of substituted cyclohexenols and cyclohexadienols. Tetrahedron Letters. 1982;23(50):5299-302. https://doi.org/…
[cited by applicant]
Cacchi et al., Palladium-catalyzed carbonylation of enol triflates. A novel method for one-carbon homologation of ketones to ?,?-unsaturated carboxylic acid derivatives. Tetrahedron Letters. 26(8), 1985, pp. 1109-1112.
[cited by applicant]
Chung et al., Sequential Nitromethane Conjugate Addition/Elimination—PD-Catlyzed Allylation of beta-Trifloxy Acrylates. Application to Carbapenem Synthesis. Org Lett. 1999;1(11):1783-1785.
[cited by applicant]
Dang et al., Determination of trace cantharidin in plasma and pharmacokinetic study in beagle dogs using gas chromatography-mass spectrometry. J Anal Toxicol. Sep. 2009;33(7):384-8.
[cited by applicant]
Dauben et al., Organic reactions at high pressure. Cycloadditions with furans. J. Am. Chem. Soc. 1976;98(7):1992-1993.
[cited by applicant]
Dauben et al., Organic reactions at high pressure. The preparative scale synthesis of cantharidin. J. Org. Chem. 1985;50 (14):2576-2578.
[cited by applicant]
Dauben et al., Simple, efficient total synthesis of cantharidin via a high-pressure Diels-Alder reaction. J. Am. Chem. Soc. 1980;102(22):6893-6894.
[cited by applicant]
Gaul, Part I. Diels-Alder reactions performed in highly polar media. Part II. Reactions of allenylstannanes with in situ generated immonium ions. Dissertation. Indiana University, Bloomington Indian, 1990. 152 pages.
[cited by applicant]
Grieco et al., Dramatic rate accelerations of Diels-Alder reactions in 5 M lithium perchlorate-diethyl ether: the cantharidin problem reexamined. J. Am. Chem. Soc. 1990;112(11):4595-4596.
[cited by applicant]
Handy et al., Lithium Trifluoromethanesulfonimide in Acetone Or Diethyl-ether As a Safe Alternative To Lithium Perchlorate in Diethyl-ether for Effecting Diels-alder Reactions. Unexpected Influence of the Counterion On …
[cited by applicant]
Hollis et al., Homogeneous catalysis. Titanium complex [Ti(Cp)2(CF3SO3)2] and zirconium complex [Zr(Cp)2(CF3SO3)2THF], efficient catalysts for the Diels-Alder reaction. Organometallics. Aug. 1, 1992;11(8):2745-8. https:…
[cited by applicant]
Hollis et al., Homogenous Catalysis: Transition Metal Based Lewis Acid Catalysts. Tetrahedron. 1993;49(25):5415-30. doi: https://doi.org/10.1016/S0040-4020(01)87259-8.
[cited by applicant]
Houk et al, On Lewis Acid catalysis of diels-alder reactions. J Am Chem Soc. Jun. 13, 1973;95(12):4094-4096.
[cited by applicant]
Huang, Catalysts for Hetero Diels-Alder Reaction of Imines. Chinese Journal of Organic Chemistry. Oct. 2003;23(10):1064-75.
[cited by applicant]
Hubbard et al., Lewis Acid Catalyzed Diels?Alder Reactions of Highly Hindered Dienophiles. J. Org. Chem. 1998;63(12):4143-4146.
[cited by applicant]
Hunt et al., Why do catalytic quantities of lewis acid generally yield more product than 1.1 equiv in the intramolecular diels-adler reaction with a furan diene? Competitive complexation NMR studies provide an answer. J…
[cited by applicant]
Kharitonov et al., Synthetic transformations of higher terpenoids: VIII. [4+2]-Cycloaddition reactions of lambertianic acid. Russian J Organic Chem. 2003;39(1):57-74.
[cited by applicant]
Kronemyer et al., Verrica develops a solution for common warts. Retrieved from www.dermatologytimes.com. Nov. 13, 2017. 1 page.
[cited by applicant]
Lange et al., Synthesis of 4-carboxy-2-thiabicyclo [3.2.0] Heptan-6-ones via 3-carboxy-2,3-dihydrothiophenes: potential ?-lactamase inhibitors. Tetrahedron Lett. 1985;26(15):1791-1794.
[cited by applicant]
Magyarosy et al., Cycloaddition approach to the curing of polyimides via precursor containing thiophene-S,S-dioxide. Hetero Chem. 2006;17(7):648-652.
[cited by applicant]
Mehdinia et al., Analysis of cantharidin in false blister beetles (Coleoptera: Oedemeridae) by headspace solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sc…
[cited by applicant]
Moed et al., Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol. Oct. 2001;137(10):1357-60. doi: 10.1001/archderm.137.10.1357.
[cited by applicant]
Nikbakhtzadeh et al., Origin, transfer and distribution of cantharidin-related compounds in the blister beetle
[cited by applicant]
Opposition to Patent Application No. 252907 by Wavelength Enterprises, Ltd., filed Mar. 1, 2021. 78 pages.
[cited by applicant]
Pagni et al., A chemical, spectroscopic, and theoretical assessment of the lewis acidity of LiClO4 in Diethyl Ether. J. Org Chem. 1993;58:3130-3133.
[cited by applicant]
Prabhakar Reddy et al., Synthesis, cytotoxic activity and structure-activity relationships of hedychenone analogues. Bioorg Med Chem Lett. Apr. 15, 2010;20(8):2525-8. doi: 10.1016/j.bmcl.2010.02.101. Epub Mar. 3, 2010.
[cited by applicant]
Rosenberg et al., Cantharidin treatment of warts at home. Arch Dermatol. Aug. 1977;113(8):1134.
[cited by applicant]
Rossy et al., Aromatization of Dihyrothiophenes. Thiophenesaccharin: A Sweet Surprise. J Org Chem. 1980;45:617-620.
[cited by applicant]
Rudo et al., Cantharidin—als Potenzmittel entzaubert, aber Oct. 1, 2013. Chemie in Unserer Zeit. vol. 47, Issue 5. pp. 310-316. With Supporting Information.
[cited by applicant]
Schenck et al., Ausfuhrliche Mitteilung erfolgt an anderer Stelle. Naturwissenshaften Oct. 15, 1953; 40: 581.
[cited by applicant]
Song et al., Ionic liquids as powerful media in scandium triflate catalysed Diels-Alder reactions: significant rate acceleration, selectivity improvement and easy recycling of catalyst. Chem Commun. 2001;12:1122-3.
[cited by applicant]
Sperry et al., Studies on the Diels-Alder reaction of annulated furans: application to the synthesis of substituted phenanthrenes. Tetrahedron Letters. Apr. 18, 2005;46(16):2789-93. Doi: 10.1016/j.tetlet.2005.02.148.
[cited by applicant]
Stork et al., A Stereospecific Synthesis of Cantharidin. J. Am. Chem. Soc., 1953;75(2):384-392.
[cited by applicant]
Stork et al., Cantharidin. A Stereospecific Total Synthesis. J. Am. Chem. Soc. 1951;73(9):4501-4501.
[cited by applicant]
Terao et al., Thiocarbonyl Ylides. VI. New Generation of Thiocarbonyl Ylides from Organosilicon Compounds Containing Sulfur and Their 1, 3-Cycloadditions. J-STAGE. 1987;35(5):1734-1740.
[cited by applicant]
Torbeck et al., Cantharidin: a comprehensive review of the clinical literature. Dermatol Online J. Jun. 15, 2014;20(6):13030/qt45r512w0.
[cited by applicant]
Tseng et al., Synthesis and Evaluation of Cantharidinimides on Human Cancer Cells. J Exp Clin Med. Oct. 2012;4(5):280-283.
[cited by applicant]
Verma et al., Bioactive component, cantharidin from Mylabris cichorii and its antitumor activity against Ehrlich ascites carcinoma. Cell Biol Toxicol. Jun. 2012;28(3):133-47. doi: 10.1007/s10565-011-9206-6. Epub Mar. 9,…
[cited by applicant]
White et al., Dihydrothiophenes as precursors to fused quinolines, quinolones and coumarins via o-quinodimethane intermediates. Tetrahedron 52(9), Feb. 26, 1996, pp. 3117-3134.
[cited by applicant]
White et al., Quinoline Analogues of Ortho-Quinodimethane. Tetrahedron Lett. 1995;36(33):5983-5986.
[cited by applicant]
[No Author Listed] Journal of Organic Chemistry Author Guidelines. Last updated May 5, 2022. 3 pages.
[cited by applicant]
Chen et al., Precautions with gentian violet: skin marking made sterile, effective, and economical. Am J Infect Control. Apr. 2009;37(3):244-6. doi: 10.1016/j.ajic.2008.06.005. Epub Oct. 14, 2008.
[cited by applicant]
Earle et al., Diels-Alder reactions in ionic liquids. A safe recyclable alternative to lithium perchlorate-diethyl ether mixtures. Green Chem. Feb. 1999;1:23-25. doi: 10.1039/A808052F.
[cited by applicant]
Gaines et al., Trimethylgallium. In: Inorganic Syntheses. Parshall, ed. Jan. 1, 1974. Retrieved from <https://onlinelibrary.wiley.com/doi/10.1002/9780470132463.ch45> on Apr. 12, 2023. 3 pages.
[cited by applicant]
Harreus et al., 2-Pyrrolidone. Ullmann's Encyclopedia of Industrial Chemistry. 2000. doi: doi: 10.1002/14356007.a22_457.pub2.
[cited by applicant]
Pulce et al., Denatonium Benzoate. Human Toxicol. Jan. 1996;1-12. Accessed Sep. 12, 2022 from <https://www.sciencedirect.com/topics/medicine-and-dentistry/denatonium-benzoate>.
[cited by applicant]
Extended European Search Report, mailed Apr. 11, 2024 for European Application No. 24153182.1.
[cited by applicant]